Table 4.
Clinical trials on adoptive cell transfer therapy
|
Clinical trials #
|
Phase
|
Aim and design
|
Status
|
| NCT03563170 | Phase 1b/2 | Combining innate high-affinity natural killer (hank) cell therapy with adenoviral and yeast-based vaccines to induce t-cell responses vs sorafenib | Withdrawn |
| NCT03008343 | Phase I/II | Combination of IRE and NK cells immunotherapy vs IRE alone | Completed, no result posted |
| NCT01147380 | Phase I | Natural killer cell therapy for hepatoma liver transplantation (MIAMINK); To evaluate feasibility and safety of the adoptive transfer of activated NK cells | Completed; No adverse events reported |
| NCT02008929 | Phase II | To evaluate the safety and efficacy of injecting MG4101 (ex vivo expanded allogeneic NK cell) as a secondary treatment after curative liver resection in advanced HCC | Completed; No study results posted |
| NCT01749865 | Phase III | CIK treatment in 200 patients with HCC who underwent radical resection | Completed; No study results posted |
| NCT02723942 | Phase I/II | To evaluate the safety and efficacy of CAR-T cell immunotherapy for GPC3 positive hepatocellular carcinoma | Withdrawn due to revision of local regulations |
| NCT03198546 | Phase I | GPC3 and/or TGF-β targeting CAR-T cells in | Recruiting |
| NCT03130712 | Phase I/II | GPC3-targeted T cells by intratumor injection for advanced HCC (GPC3-CART) | Unknown |
| NCT02715362 | Phase I/II | GPC3 redirected autologous t cells for advanced HCC (GPC3-CART) | Unknown |
| NCT03013712 | Phase I/II | GPC3-targeted T cells by intratumor injection for advanced HCC (GPC3-CART) | Unknown |
| NCT03349255 | Phase I | Autologous ET1402L1-CAR T cells in AFP expressing HCC | Terminated and will study new T-cell construct |
| NCT02905188 | Phase I | To find the biggest dose of GLYCAR T cells that is safe, to see how long they last in the body, to learn what the side effects in GPC3-positive HCC | Recruiting patients; Partial response with no toxicities |
| NCT03146234 | Single arm, open-label pilot study | to determine the safety and efficacy of CAR-GPC3 T cells in patients with relapsed or refractory HCC following cyclophosphamide and fludarabine | Completed; Had a tolerable toxicity profile with no grade 3/4 neurotoxicity; Overall survival 9.1 |
| NCT02395250 | Phase I | To evaluate the safety and effectiveness of anti-GPC3 CAR T in patients with relapsed or refractory HCC | Completed, no result posted |
| NCT03980288 | Phase I | 4th generation chimeric antigen receptor T cells targeting glypican-3 (CAR-GPC3 T cells) in patients with advanced HCC | Recruiting patients |
| NCT04121273 | Phase I | GPC3-targeted CAR-T cell for treating GPC3 positive advanced HCC | Recruiting patients |
| NCT03884751 | Phase I | Clinical study of chimeric antigen receptor T cells targeting glypican-3 (CAR-GPC3 T cells) in patients with advanced HCC | Recruiting patients |
| NCT04093648 | Phase I | T cells co-expressing a second generation glypican 3-specific chimeric antigen receptor with cytokines interleukin-21 and 15 as immunotherapy for patients with liver cancer (TEGAR) | Withdrawn (the key elements of this study were incorporated into another study) |
| NCT03013712 | Phase I/II | CAR T cells targeting EpCAM positive cancer (CARTEPC); To evaluate the safety and efficacy of chimeric antigen receptor (CAR) T cells targeting EpCAM | Unknown |
NK: Natural killer; IL: Interleukin; HCC: Hepatocellular carcinoma; CIK: Cytokine-induced killer; TIL: Tumor-infiltrating lymphocytes; RFA: Radiofrequency ablation; CAR: Chimeric antigen receptor; Adenoviral and Yeast based vaccines: ETBX-011, GI-4000, avelumab, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, and N-803; IRE: Irreversible electroporation; LDC: Lymphodepleting conditioning; GLYCAR: Glypican 3-specific chimeric antigen receptor expressing T cells for hepatocellular carcinoma; HCC: Hepatocellular carcinoma.